Una possibile alternativa alla terapia infusiva con i farmaci inotropi positivi tradizionali

Translated title of the contribution: Levosimendan in heart failure

Laura Scelsi, Carlo Campana, Stefano Ghio, Lorenzo Monti, Cristina Opasich, Stefania De Feo, Franco Cobelli, Mario Orlandi, Giuseppe Di Pasquale, Luigi Tavazzi

Research output: Contribution to journalArticlepeer-review


Clinical trials investigating traditional inotropic agents in patients with heart failure demonstrated an increased mortality rate (odds ratio 1.50; IC=0.51 - 3.92), high incidence of discontinuation of infusion therapy (odds ratio 0.46; IC=0.083 - 2.29) due to major side effects and, most of all, a limited clinical benefit (odds ratio 0.75; IC=1.42 - 0.08). On this background a new class of inotropic drugs, the calcium-sensitisers, have been developed. The safety and efficacy of levosimendan (Simdax) has been recently demonstrated in trials (LIDO e RUSSLAN) in patients with heart failure due to ischemic and not ischemic disease. Twenty-six patients with decompensated heart failure of different etiology have been treated with 24 hour infusion of levosimendan. In this experience the levosimendan improved the clinical status and the left ventricular ejection fraction.

Translated title of the contributionLevosimendan in heart failure
Original languageItalian
Pages (from-to)376-383
Number of pages8
JournalRecenti Progressi in Medicina
Issue number7-8
Publication statusPublished - Jul 2004

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Levosimendan in heart failure'. Together they form a unique fingerprint.

Cite this